Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2019 Annual Meeting

NEW YORK, NY Flatiron Health today announced 21 abstracts accepted for presentation at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 – June 4 in Chicago. The research, spanning multiple tumor types and areas of study, utilized Flatiron’s high-quality, real-world oncology datasets. The research to be presented includes collaborations between Flatiron and the U.S. Food and Drug Administration, National Cancer Institute, Fight Colorectal Cancer, Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Tesaro, Roche/Genentech and Foundation Medicine. The presentation schedule and links to abstracts can be found below. Learn more about our abstracts by clicking on each link or see our recent blog post for more information. Plenary Session Affordable Care Act (ACA) Medicaid Expansion Impact on Racial Disparities in Time to Cancer Treatment Presenting Author: Amy Davidoff, PhD (Yale Cancer Center) Date/Time: June 2 — 1:45 – 2:00pm Abstract: #LBA1 Location: Hall B1 Track: Special Sessions Poster Discussion Genomic Characterization of Lung Tumors and Metastatic Sites in Advanced NSCLC First Author: Melinda Willard (Eli Lilly and Company) Date/Time: June 2 — 4:30 – 6:00pm Abstract: #2014 Poster: #203 Location: S404 Track: Central Nervous System Tumors Poster Sessions (Location: Hall A) Organ Dysfunction and Clinical Outcomes in Patients Treated with Immune Checkpoint Inhibitors First Author: Qi Li, PhD (U.S. Food and Drug Administration) Date/Time: June 1 — 8:00 – 11:00am Abstract: #2569 Poster: #213 Track: Developmental Immunotherapy and Tumor Immunobiology Tumor Mutational Burden and PD-L1 Expression as Predictors of Response to Immunotherapy in NSCLC First Author: Emily Castellanos, MD, MPH (Flatiron Health) Date/Time: June 1 — 8:00 – 11:00am Abstract: #2630 Poster: #274 Track: Developmental Immunotherapy and Tumor Immunobiology Impact of Oncology Care Model Reporting Requirements on Quality of Care First Author: Emily Castellanos, MD, MPH (Flatiron Health) Date/Time: June 1 — 1:15 – 4:15pm Abstract: #6620 Poster: #311 Track: Health Services Research, Clinical Informatics, and Quality of Care Using Real-World Cohorts to Assess the Generalizability and Relevance of Randomized Clinical Trials First Author: Caroline Bennette, MPH, PhD (Flatiron Health) Date/Time: June 1 — 1:15 – 4:15pm Abstract: #6540 Poster: #231 Track: Health Services Research, Clinical Informatics, and Quality of Care Concurrent or Layered Treatment with Radium-223 and Enzalutamide or Abiraterone Plus Prednisone/Prednisolone: A Retrospective Study of Real-World Clinical Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer. First Author: Neal Shore, FACS, MD Date/Time: June 1 — 1:15 – 4:15pm Abstract: #5026 Poster: #138 Track: Health Services Research, Clinical Informatics, and Quality of Care Recurrence of Ovarian Cancer in BRCAwt Patients without Maintenance Therapy: Real-World Evidence First Author: Melinda Louie-Gao, PhD (TESARO, Inc.) Date/Time: June 1 — 1:15 – 4:15pm Abstract: #5547 Poster: #370 Track: Gynecologic Cancer Risk Factors for Progression or Death in Ovarian Cancer Patients who Completed First-Line Platinum Treatment First Author: Shannon Neville Westin, MD (MD Anderson Cancer Center) Date/Time: June 1 — 1:15 – 4:15pm Abstract: #5547 Poster: #371 Track: Gynecologic Cancer Clinical Characteristics, Treatment Patterns, and Overall Survival in Advanced NSCLC Patients With and Without Brain Metastases First Author: Emily Nash Smyth, PharmD (Eli Lilly and Company) Date/Time: June 2 — 8:00 – 11:00am Abstract: #2035 Poster: #224 Track: Central Nervous System Tumors Identification and Use of Treatment Options in Patients with Advanced Non-Small Cell Lung Cancer After Comprehensive Genomic Profiling: A Real-World Study First Author: Celine Mascaux, MD, PhD (Aix-Marseille University) Date/Time: June 2 — 8:00 – 11:00am Abstract: #9076 Poster: #399 Track: Lung Cancer—Non-Small Cell Metastatic Real-World Evidence of Male Breast Cancer Patients Treated with Palbociclib in Combination with Endocrine Therapy First Author: Cynthia Huang Bartlett, MD (Pfizer) Date/Time: June 2 — 8:00 – 11:00am Abstract: #1055 Poster: #136 Track: Breast Cancer—Metastatic Real-World Practice Patterns and Impact of PD-L1 Expression Testing in Patients with Advanced Non-Small Cell Lung Cancer First Author: Michael Leapman, MD (Yale School of Medicine) Date/Time: June 2 — 8:00 – 11:00am Abstract: #9059 Poster: #382 Track: Lung Cancer—Non-Small Cell Metastatic Real-World Utilization of EGFR TKI Therapies and Treatment Outcomes in Patients with Advanced EGFR-Sensitizing Mutation-Positive NSCLC First Author: Gregory J. Riely, MD, PhD (Memorial Sloan Kettering Cancer Center) Memorial Sloan Kettering Cancer Center Date/Time: June 2 — 8:00 – 11:00am Abstract: #9062 Poster: #385 Track: Lung Cancer—Non-Small Cell Metastatic Time-to-Treatment Discontinuation and Real-World Progression-Free Survival as Endpoints for Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive NSCLC Patients First Author: Robert Charles Doebele, MD, PhD (University of Colorado) Date/Time: June 2 — 8:00 – 11:00am Abstract: #9070 Poster: #393 Track: Lung Cancer—Non-Small Cell Metastatic Validation of Broad Panel Clinical Sequencing-Based Genomic Risk Stratification in Patients with Advanced Lung Adenocarcinomas First Author: Sam Whipple, MSPH (Genentech) Date/Time: June 2 — 8:00 – 11:00am Abstract #9113 Poster #436 Track: Lung Cancer—Non-Small Cell Metastatic Chromosome 1 Abnormalities and Clinical Outcomes in Multiple Myeloma in the Era of Novel Agents First Author: Smith Giri, MBBS (Yale School of Medicine) Date/Time: June 3 — 8:00 – 11:00am Abstract: #8044 Poster: #370 Track: Hematologic Malignancies—Plasma Cell Dyscrasia Utilization and reach of the Fight Colorectal Cancer Late Stage MSS CRC Clinical Trial Finder First Author: Reese Garcia, MPH (Fight Colorectal Cancer) Date/Time: June 3 — 8:00 – 11:00am Abstract: #3561 Poster: #53 Track: Gastrointestinal (Colorectal) Cancer A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by gBRCA Mutation Status First Author: Kimmie McLaurin, MS (AstraZeneca) Date/Time: June 3 — 1:15 – 4:15pm Abstract: #1563 Poster: #57 Track: Cancer Prevention, Hereditary Genetics, and Epidemiology Burden of Thrombocytopenia in Adult Cancer Patients Receiving Chemotherapy First Author: Gerald Soff, MD (Memorial Sloan Kettering Cancer Center) Date/Time: June 3 — 1:15 – 4:15pm Abstract: #1555 Poster: #49 Track: Cancer Prevention, Hereditary Genetics, and Epidemiology Treatment Characteristics of Patients with Locally Advanced or Metastatic Urothelial Cancer (mUC) Receiving Checkpoint Inhibitor Monotherapy in a US Clinical Practice First Author: Alicia Morgans, MD, MPH (Northwestern University) Date/Time: June 3 — 1:15 – 4:15pm Abstract: #4526 Poster: #352 Track: Genitourinary (Nonprostate) Cancer About Flatiron Health Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Media Contact Nina Toor press@flatiron.com